HOOK - Hookipa: Data Readouts Of 2021's HB-101 HB-201 And HB-201/-202 Hold Promising Upside

• Hookipa Pharma is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics from its arenavirus immune-system reprogrammer platform.
• Hookipa has an infectious disease/oncology pipeline of six therapeutics. including three in clinical trials including HB-101 for CMV (Phase 2), HB-201 for HPV16+ Cancer (Phase 1/2), and HB-201/-202 for HPV16+ Cancer (Phase 1).
• Hookipa is operating with a low cash basis of $82M, but after +$69.3M from the December equity offering (total cash: $151M), the company has resources for 2-3 years of cash burn (-$44M).
• Hookipa has several catalysts for 2021, with the earliest being mid-2021's HB-201 reporting Phase 1/2 efficacy data for HPV16+ Cancer.
• In summary, the author projects Hookipa Pharma as a "buy" at a 5-7 year price target of $78.5 (+578% upside, CAGR of 28%).

For further details see: